Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04272242 · ClinicalTrials.gov registry record · Phase 2
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT04272242 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 37 participants.
The verdict
NCT04272242, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study evaluated the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT was given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected individuals.
Interventions
- DRUG Dolutegravir (DTG)
- DRUG Isoniazid (INH)
- DRUG Rifapentine (RPT)
- DIETARY_SUPPLEMENT Pyridoxine (Vitamin B6)
- DRUG Antiretroviral Therapy (ART)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-02-27 |
| Est. Completion | 2021-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04272242
The ClinicalTrials.gov registry entry for NCT04272242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dolutegravir (DTG) is the first listed.
NCT04272242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04272242 about?
NCT04272242 is a clinical study titled "Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals". This study evaluated the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT was given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected individuals.
What is the current status of trial NCT04272242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2021-02-27. Estimated completion is 2021-12-27.
What interventions are being tested in trial NCT04272242?
The interventions under investigation include: Dolutegravir (DTG) (DRUG), Isoniazid (INH) (DRUG), Rifapentine (RPT) (DRUG), Pyridoxine (Vitamin B6) (DIETARY_SUPPLEMENT), Antiretroviral Therapy (ART) (DRUG).
Who is sponsoring clinical trial NCT04272242?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.